Supriya Lifescience Limited's Board of Directors approved the company's unaudited financial results for Q3 FY26 and made significant governance changes, including the appointment of two new independent directors and reconstitution of board committees. The pharmaceutical company demonstrated robust operational performance with double-digit revenue growth while advancing strategic initiatives.

Board Meeting Outcomes and Financial Results Approval

The Board of Directors convened on February 09, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The meeting, which commenced at 3:00 PM and concluded at 5:00 PM, addressed key governance and financial matters under Regulation 30 of SEBI (LODR) Regulations, 2015.

Financial Performance Highlights

The company's Q3 FY26 financial results demonstrated strong growth momentum across key performance metrics:

For the nine-month period ended December 31, 2025, revenue from operations reached ₹5,513.47 Mn compared to ₹5,123.76 Mn in the corresponding previous period, representing growth of 7.6%.

Key Director Appointments

The board approved significant changes to its composition with the appointment of two new independent directors:

Mr. Manish Panchal brings over 32 years of cross-industry experience spanning chemicals, logistics, pharmaceuticals, and healthcare sectors. His expertise includes strategy, operational excellence, business development, and investment banking. Mr. Kothandaraman Hari contributes 28 years of capital markets experience, having served as Executive Vice President at NSE, leading strategic initiatives across multiple asset classes.

Board Committee Reconstitution

Following the new appointments, the company reconstituted its key board committees:

Audit Committee:

• Mr. Hari K. (Chairman)
• Dr. Ganapati Dadasaheb Yadav (Member)
• Dr. Satish Waman Wagh (Member)
• Mr. Manish Panchal (Member)

Nomination and Remuneration Committee:

• Mr. Hari K. (Chairman)
• Dr. Sunil Subhash Bhagwat (Member)
• Mr. Manish Panchal (Member)

Stakeholders' Relationship Committee:

• Mr. Manish Panchal (Chairman)
• Dr. Saloni Satish Wagh (Member)
• Dr. Satish Waman Wagh (Member)

Independent Director Re-appointment

The board also approved the re-appointment of Dr. Neelam Yashpal Arora (DIN: 01603068) as Non-Executive Independent Woman Director for a second consecutive term of five years, effective from March 25, 2026, to March 24, 2031, subject to shareholder approval. Dr. Arora brings over 31 years of teaching experience and 10 years of administrative experience in education, with expertise in commerce, taxation, economics, and law.

Cost Structure and Exceptional Items

The company reported an exceptional item of ₹4.58 Mn related to the impact of New Labour Codes implemented by the Government of India effective November 21, 2025. The codes consolidate 29 existing labour legislations into four unified frameworks covering wages, social security, industrial relations, and occupational safety.

Supriya Lifescience has reported a robust performance for the second quarter of fiscal year 2026, marking a significant recovery from the previous quarter and reaffirming its growth trajectory.

Financial Highlights

The company achieved a revenue of INR 200.00 crores in Q2 FY26, representing a 20% year-on-year growth and a substantial 38% sequential increase. This performance underscores the company's resilience and ability to overcome operational challenges effectively.

Key financial metrics for Q2 FY26 include:

The company's EBITDA stood at INR 73.00 crores, up 12% year-on-year and 41% sequentially, with an EBITDA margin of 36.00%, aligning with the company's guidance.

Operational Performance

Exports continue to be the cornerstone of Supriya Lifescience's business, accounting for 81% of Q2 FY26 revenues. The company has made significant progress in its backward integration efforts, with 79% of Q2 FY26 revenues now fully integrated, enhancing operational efficiency.

Growth Drivers and Future Outlook

Dr. Satish Wagh, Executive Chairman and Whole-Time Director, expressed confidence in the company's growth trajectory, stating, "We are very much confident that we will be able to achieve our guidance of 20% plus growth in revenue."

The company reaffirmed its guidance of achieving around 20% annual revenue growth, with EBITDA margins in the range of 33%-35%. Supriya Lifescience remains on track to reach its target of INR 1,000.00 crore revenue by FY27, supported by:

1. A healthy product pipeline
2. 3-4 new product launches planned for the current fiscal year
3. Steady demand across key therapeutic areas including Anesthetics, Anti-diabetics, Anti-anxiety, Vitamins, and ADHD treatments

New Developments and Expansions

The Ambernath facility, a significant milestone for the company's CDMO strategy, has started validation campaigns and is progressing as planned. Commercial contributions from this facility are expected to commence from Q4 of the current fiscal year.

Dr. Saloni Wagh, Managing Director, highlighted the company's expansion into high-potential markets, stating, "Our primary focus remains on expanding into other high potential related markets. We continue to strengthen our competitiveness edge through deep backward integration, robust regulatory credentials across major markets and a broad portfolio of different products."

Conclusion

Supriya Lifescience's Q2 FY26 results demonstrate the company's ability to navigate challenges and capitalize on growth opportunities. With a strong focus on exports, backward integration, and expansion into new markets, the company appears well-positioned to achieve its growth targets and create value for stakeholders.

Investors and market watchers will be keen to observe the company's performance in the coming quarters, particularly the ramp-up of the Ambernath facility and the impact of new product launches on overall revenue growth.